Tasly Pharmaceutical Group Co., Ltd Sustainability Profile
Tasly Pharmaceutical Group Co., Ltd., commonly referred to as Tasly, is a leading player in the pharmaceutical industry, headquartered in China (CN). Founded in 1994, the company has established a strong presence in both domestic and international markets, with significant operations across Asia, Europe, and North America. Specialising in traditional Chinese medicine and modern pharmaceuticals, Tasly is renowned for its innovative products, including herbal remedies and cardiovascular treatments. The company’s commitment to research and development has led to numerous breakthroughs, positioning it as a pioneer in integrating traditional practices with contemporary science. With a robust market presence, Tasly has achieved notable milestones, including multiple certifications for its quality management systems. Its dedication to enhancing health and well-being through unique, effective solutions continues to solidify its reputation as a trusted name in the global healthcare landscape.
DitchCarbon Score
How does Tasly Pharmaceutical Group Co., Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tasly Pharmaceutical Group Co., Ltd's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tasly Pharmaceutical Group Co., Ltd's reported carbon emissions
In 2024, Tasly Pharmaceutical Group Co., Ltd reported significant carbon emissions from its operations in China, with Scope 1 emissions amounting to approximately 4,955,700 kg CO2e and Scope 2 emissions reaching about 489,887,060 kg CO2e. This data highlights the company's substantial carbon footprint, particularly in its energy consumption and direct operational activities. The company has not disclosed any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. Furthermore, there are currently no specific reduction targets or climate pledges outlined by Tasly Pharmaceutical Group, indicating a potential area for improvement in their sustainability strategy. In terms of emissions intensity, the company has reported emissions per unit for aluminium and steel production, with values of approximately 17.3 kg CO2e/kg and 4.8 kg CO2e/kg, respectively, for 2024. This data reflects the environmental impact of their manufacturing processes. Overall, while Tasly Pharmaceutical Group has provided some emissions data, the absence of reduction targets and comprehensive climate commitments suggests that the company may need to enhance its climate action initiatives to align with industry standards and expectations.
How Carbon Intensive is Tasly Pharmaceutical Group Co., Ltd's Industry?
How Carbon Intensive is Tasly Pharmaceutical Group Co., Ltd's Location?
Tasly Pharmaceutical Group Co., Ltd's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Tasly Pharmaceutical Group Co., Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
